CCND1 amplification and CDKN2A mutations, and Rb presence are considered as biomarkers to predict the activity of CDK4/6 inhibitors in HPV-negative HNSCC [43–45]. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.